查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2089003

感染疾病疫苗市場：按疫苗類型、給藥途徑、最終用戶和分銷管道分類的全球市場預測 – 2026-2032 年

Infectious Vaccines Market by Vaccine Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，感染疾病疫苗市場規模將達到 669.8 億美元，複合年成長率為 9.76%。

主要市場統計數據
基準年 2025 348.8億美元
預計年份：2026年 382.3億美元
預測年份：2032年 669.8億美元
複合年成長率 (%) 9.76%

感染疾病疫苗市場概覽

根據世界衛生組織（世衛組織）估計，感染疾病疫苗仍是全球醫療保健領域最具影響力的醫療技術之一，每年可預防約350萬至500萬人死亡。感染疾病疫苗市場受持續成長的需求驅動，這些需求包括兒童免疫接種、成人加強免疫計劃、疫情防範、旅行者疫苗接種以及預防呼吸道疾病、蟲媒傳染病和新興感染疾病。

感染疾病疫苗領域的變革性變化

感染疾病疫苗領域的格局正從間歇性疾病控制轉向持續免疫系統的發展。新冠肺炎疫情加速了監管機構間的合作、真實世界安全性監測、對低溫運輸的投資、基因組監測以及基於平台的疫苗開發，從而加快了流感、呼吸道合胞病毒、肺炎鏈球菌感染、人類乳突病毒、瘧疾、登革熱、結核病以及未來通用感染疾病的疫苗研發進程。

人工智慧對疫苗創新的累積影響

人工智慧（AI）的應用日益廣泛，涵蓋疫苗研發、抗原篩選、抗原決定位定位、免疫抗原性預測、臨床試驗最佳化、藥物安全監測和生產分析等許多領域。人工智慧模型能夠加速候選疫苗的篩檢，並支援對高度變異的病原體病毒株（包括流感病毒、SARS-CoV-2病毒和其他呼吸道病毒）的監測。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區因其大規模的新生兒群體、不斷擴大的國內疫苗生產能力以及政府對免疫接種投入的增加，而被列為重點關注區域。中國、印度、日本、韓國和澳洲在疫苗供應、研發、強化監管以及先進的臨床應用方面均發揮獨特的作用。北美地區憑藉著成熟的監管體系、成人免疫接種計劃、充足的生物醫學研究經費以及美國疾病管制與預防中心和加拿大衛生署製定的疫苗接種指南，仍然是創新和商業化的重要中心。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體進行分析。

在東協市場，我們正透過公共計畫、區域製造夥伴關係以及擴大登革熱、流感、麻疹和呼吸道病原體的監測系統來提高疫苗接種率。海灣合作理事會（GCC）正在加大對醫療保健、生命科學本土化、醫療準備和疫情防範的投入，將感染疾病疫苗作為國家衛生安全的戰略支柱。

對主要感染疾病疫苗市場國家的關鍵洞察。

美國在疫苗生物技術、聯邦採購能力、真實世界數據（RWE）基礎設施以及成人免疫商業化方面處於主導地位。加拿大則著重於公共衛生指南、流感預防、公平取得以及省級免疫實施。墨西哥和巴西是拉丁美洲的關鍵市場，巴西的公共免疫基礎設施和本地生產能力促進了大規模疫苗接種，而墨西哥則透過兒童、流感、HPV和集體爆發預防計畫來維持需求。在歐洲，英國、德國、法國、義大利和西班牙透過國家免疫規劃、老化、旅行醫學以及引入呼吸道合胞病毒（RSV）、肺炎球菌、流感、HPV和聯合疫苗來維持需求。俄羅斯則保持其國內疫苗生產能力，並將免疫接種作為公共部門的優先事項。

感染疾病疫苗產業領導者使用的實用建議

產業領導者應優先考慮多樣化的抗原組合、穩健的供應鏈以及能夠快速適應流行病、季節性疾病和地方性疾病需求的平台技術。每個組織都必須使其產品上市策略與國家免疫規劃、保險公司的證據要求、真實世界療效數據以及特定人口的疾病負擔分析保持一致。

感染疾病疫苗市場分析的調查方法

本執行摘要基於公開且檢驗的資料資訊來源，包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、聯合國兒童基金會 (UNICEF)、全球免疫技術諮詢小組 (Gabi)、各國免疫技術諮詢小組、監管機構、同行評審文獻、公共衛生監測系統以及經認可的全球衛生資料庫，透過二手研究編製而成。分析重點在於疫苗接種率、疾病負擔、平台創新、採購系統、安全監測和地方衛生政策等方面的證據。

結論：感染疾病疫苗市場的策略展望

感染疾病疫苗市場正進入一個更具策略性的階段，其特點是平台彈性、人工智慧驅動的藥物研發、公私合營、基因組監測以及擴大成人免疫接種範圍。長期價值取決於可靠的供應、對監管機構的信任、真實世界數據、對疫苗的信心，以及同時滿足高所得者加強免疫接種市場和低疫苗接種率人群的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：感染疾病疫苗市場：依疫苗類型分類

  • 組合型
    • Hib結合疫苗
    • 腦膜炎雙球菌結合疫苗
    • 肺炎鏈球菌結合疫苗
  • 失活
    • 甲型肝炎
    • 流感
    • 脊髓灰質炎
    • 狂犬病
  • 減毒活病毒疫苗
    • 流感減毒活疫苗（LaIV）
    • 麻疹
    • 口服脊髓灰質炎疫苗
    • 德國麻疹
    • 水痘
  • mRNA
    • 脂質奈米顆粒mRNA
    • 自擴增mRNA
  • 次單元
    • 蛋白質次單元
    • 類病毒顆粒
  • 類毒素
    • 白喉
    • 百日咳
    • 破傷風
  • 病毒載體
    • 腺病毒
    • MVA
    • VSV

第8章：感染疾病疫苗市場：依給藥途徑分類

  • 皮內給藥
  • 肌肉內部
  • 鼻內給藥
  • 口服
  • 皮下

第9章：感染疾病疫苗市場：依最終用戶分類

  • 診所
    • 一般醫療
    • 專業醫療機構
  • 醫院
    • 私人的
    • 民眾
  • 藥局
    • 線上
    • 零售
  • 公共衛生中心
    • 農村
    • 都市區

第10章：感染疾病疫苗市場：依分銷管道分類

  • 政府機構
    • 按地區
    • 各國
  • 醫院藥房
    • 在醫院裡
    • 門診
  • 網路藥房
    • 直接的
    • 平台
  • 零售藥房
    • 鏈
    • 獨立的

第11章：感染疾病疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：感染疾病疫苗市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：感染疾病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Adimmune Corporation
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat BIoTech
  • Biological E Limited
  • BioNTech SE
  • CanSino Biologics
  • China National BIoTechnology Group
  • CSL Limited
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India
  • Sinovac BIoTech Ltd.
  • Valneva SE
  • VBI Vaccines, Inc.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market is projected to grow by USD 66.98 billion at a CAGR of 9.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.88 billion
Estimated Year [2026] USD 38.23 billion
Forecast Year [2032] USD 66.98 billion
CAGR (%) 9.76%

Infectious Vaccines Market Introduction

Infectious vaccines remain one of the highest-impact health technologies in global healthcare, preventing an estimated 3.5 million to 5 million deaths annually according to the World Health Organization. The infectious vaccines market is being shaped by sustained demand for pediatric immunization, adult booster programs, pandemic preparedness, travel vaccination, and protection against respiratory, vector-borne, and emerging infectious diseases.

Commercial momentum is supported by expanded use of mRNA, viral vector, recombinant protein, conjugate, live-attenuated, inactivated, and adjuvanted vaccine platforms. At the same time, public-sector procurement, Gavi-supported programs, national immunization schedules, and regulatory harmonization continue to influence access, pricing, and launch sequencing across developed and emerging markets.

Transformative Shifts in the Infectious Vaccines Landscape

The infectious vaccines landscape is shifting from episodic disease control toward continuous immunization readiness. COVID-19 accelerated regulatory collaboration, real-world safety monitoring, cold-chain investment, genomic surveillance, and platform-based vaccine development, creating faster pathways for vaccines targeting influenza, RSV, pneumococcal disease, HPV, malaria, dengue, tuberculosis, and future zoonotic threats.

Manufacturers are also adapting to combination vaccines, thermostable formulations, needle-free delivery research, and localized production. Demand is increasingly influenced by vaccine confidence, supply resilience, equitable access, antimicrobial resistance prevention, and the ability to demonstrate real-world effectiveness across infants, adolescents, adults, older adults, pregnant populations, travelers, and immunocompromised groups.

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Artificial intelligence is increasingly used across vaccine discovery, antigen selection, epitope mapping, immunogenicity prediction, clinical trial optimization, pharmacovigilance, and manufacturing analytics. AI-enabled models can accelerate candidate screening and support strain surveillance for pathogens with high mutation rates, including influenza, SARS-CoV-2, and other respiratory viruses.

The cumulative impact of AI is most visible when combined with high-quality genomic surveillance, electronic health records, immunization registries, and post-market safety databases. However, industry leaders must manage data bias, explainability, cybersecurity, validation standards, and regulatory acceptance to ensure AI improves vaccine speed without compromising safety, equity, or scientific rigor.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding domestic vaccine manufacturing, and rising government immunization investment, with China, India, Japan, South Korea, and Australia playing distinct roles in supply, R&D, regulatory strengthening, and advanced clinical adoption. North America remains a leading innovation and commercialization hub, supported by mature regulatory systems, adult immunization programs, strong biomedical research funding, and established CDC and Health Canada vaccination guidance.

Latin America continues to prioritize public procurement and regional disease control, with Brazil and Mexico central to demand for pediatric, HPV, influenza, pneumococcal, and outbreak-response vaccines. Europe benefits from centralized regulatory expertise, national immunization technical advisory groups, disease surveillance networks, and strong uptake of combination, travel, RSV, influenza, and HPV vaccines, while the Middle East is increasing investment in health security, preventive care, local manufacturing, and cold-chain infrastructure. Africa represents a critical access and impact region, where Gavi, UNICEF, WHO, Africa CDC, and national ministries support immunization against measles, polio, pneumococcal disease, rotavirus, HPV, malaria, yellow fever, cholera, and other high-burden infections.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are strengthening immunization coverage through public-sector programs, regional manufacturing partnerships, and expanded surveillance for dengue, influenza, measles, and respiratory pathogens. The GCC is investing in preventive healthcare, life sciences localization, medical countermeasure readiness, and pandemic preparedness, making infectious vaccines a strategic pillar of national health security.

The European Union provides regulatory scale through the European Medicines Agency and coordinated public health initiatives, while BRICS countries combine large population demand with growing vaccine production capacity, public procurement influence, and expanding disease surveillance systems. G7 nations remain central to vaccine R&D financing, advanced manufacturing, and global health funding, and NATO members increasingly frame vaccine resilience, stockpiling, continuity of supply, and medical countermeasures as part of biosecurity and civil preparedness.

Key Country Insights Across Major Infectious Vaccine Markets

The United States leads in vaccine biotechnology, federal procurement capacity, real-world evidence infrastructure, and adult immunization commercialization, while Canada emphasizes public health guidance, influenza prevention, equity-focused access, and provincial immunization delivery. Mexico and Brazil are important Latin American markets, with Brazil's public immunization infrastructure and local production capabilities supporting large-scale uptake, and Mexico maintaining demand through pediatric, influenza, HPV, and outbreak-prevention programs. In Europe, the United Kingdom, Germany, France, Italy, and Spain sustain demand through national immunization programs, aging populations, travel medicine, and adoption of RSV, pneumococcal, influenza, HPV, and combination vaccines; Russia maintains domestic vaccine capabilities and public-sector immunization priorities.

China and India are pivotal due to population scale, domestic production, regulatory modernization, and expanding innovation pipelines, with India also serving as a major global vaccine supplier for routine immunization programs. Japan prioritizes high-quality regulatory review, post-marketing safety, and aging-population vaccination, Australia maintains strong immunization registries and public health surveillance, and South Korea is advancing biomanufacturing, CDMO capacity, clinical research, and infectious disease preparedness.

Actionable Recommendations for Infectious Vaccine Industry Leaders

Industry leaders should prioritize diversified antigen portfolios, resilient supply chains, and platform technologies that can be rapidly adapted to outbreak, seasonal, and endemic disease needs. Organizations should align launch strategies with national immunization schedules, payer evidence requirements, real-world effectiveness data, and population-specific burden-of-disease analysis.

Executives should also invest in regional manufacturing partnerships, cold-chain optimization, pharmacovigilance automation, genomic surveillance integration, and vaccine confidence programs. Strategic differentiation will come from combination products, improved durability, simplified administration, thermostability, and robust evidence demonstrating reductions in hospitalizations, antimicrobial use, mortality, transmission, and overall healthcare costs.

Research Methodology for Infectious Vaccines Market Analysis

This executive summary is developed through secondary research using publicly available and verifiable sources, including WHO, CDC, UNICEF, Gavi, national immunization technical advisory groups, regulatory agencies, peer-reviewed literature, public health surveillance systems, and recognized global health databases. The analysis prioritizes evidence related to vaccine coverage, disease burden, platform innovation, procurement systems, safety monitoring, and regional health policy.

Insights are synthesized through data triangulation, trend mapping, technology assessment, and policy review. Qualitative interpretation is applied to compare regional demand drivers, manufacturing capabilities, regulatory dynamics, access barriers, immunization infrastructure, and competitive positioning within the infectious vaccines ecosystem, without relying on market sizing, share estimates, or forecasts.

Conclusion: Strategic Outlook for Infectious Vaccines

The infectious vaccines market is entering a more strategic phase defined by platform agility, AI-enabled discovery, public-private preparedness, genomic surveillance, and broader adult immunization. Long-term value will depend on reliable supply, regulatory trust, real-world evidence, vaccine confidence, and the ability to address both high-income booster markets and under-immunized populations.

Organizations that combine scientific innovation with equitable access, manufacturing resilience, transparent safety monitoring, and data-driven commercialization will be best positioned to capture growth opportunities while strengthening global protection against preventable infectious diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infectious Vaccines Market, by Vaccine Type

  • 7.1. Conjugate
    • 7.1.1. Hib Conjugate
    • 7.1.2. Meningococcal Conjugate
    • 7.1.3. Pneumococcal Conjugate
  • 7.2. Inactivated
    • 7.2.1. Hepatitis A
    • 7.2.2. Influenza
    • 7.2.3. Polio
    • 7.2.4. Rabies
  • 7.3. Live Attenuated
    • 7.3.1. Influenza Laiv
    • 7.3.2. Measles
    • 7.3.3. Oral Polio
    • 7.3.4. Rubella
    • 7.3.5. Varicella
  • 7.4. MRNA
    • 7.4.1. Lipid Nanoparticle MRNA
    • 7.4.2. Self-Amplifying MRNA
  • 7.5. Subunit
    • 7.5.1. Protein Subunit
    • 7.5.2. Virus-Like Particle
  • 7.6. Toxoid
    • 7.6.1. Diphtheria
    • 7.6.2. Pertussis
    • 7.6.3. Tetanus
  • 7.7. Viral Vector
    • 7.7.1. Adenovirus
    • 7.7.2. MVA
    • 7.7.3. VSV

8. Infectious Vaccines Market, by Route Of Administration

  • 8.1. Intradermal
  • 8.2. Intramuscular
  • 8.3. Intranasal
  • 8.4. Oral
  • 8.5. Subcutaneous

9. Infectious Vaccines Market, by End User

  • 9.1. Clinics
    • 9.1.1. General Practice
    • 9.1.2. Specialty
  • 9.2. Hospitals
    • 9.2.1. Private
    • 9.2.2. Public
  • 9.3. Pharmacies
    • 9.3.1. Online
    • 9.3.2. Retail
  • 9.4. Public Health Centers
    • 9.4.1. Rural
    • 9.4.2. Urban

10. Infectious Vaccines Market, by Distribution Channel

  • 10.1. Government Agencies
    • 10.1.1. Local
    • 10.1.2. National
  • 10.2. Hospital Pharmacies
    • 10.2.1. In-Hospital
    • 10.2.2. Outpatient
  • 10.3. Online Pharmacies
    • 10.3.1. Direct
    • 10.3.2. Platform
  • 10.4. Retail Pharmacies
    • 10.4.1. Chain
    • 10.4.2. Independent

11. Infectious Vaccines Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Infectious Vaccines Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Infectious Vaccines Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Adimmune Corporation
  • 15.2. AstraZeneca plc
  • 15.3. Bavarian Nordic
  • 15.4. Bharat Biotech
  • 15.5. Biological E Limited
  • 15.6. BioNTech SE
  • 15.7. CanSino Biologics
  • 15.8. China National Biotechnology Group
  • 15.9. CSL Limited
  • 15.10. Dynavax Technologies
  • 15.11. Emergent BioSolutions, Inc.
  • 15.12. GlaxoSmithKline plc
  • 15.13. Haffkine Bio-Pharmaceutical Corporation
  • 15.14. Inovio Pharmaceuticals
  • 15.15. Johnson & Johnson
  • 15.16. Merck & Co., Inc.
  • 15.17. Mitsubishi Tanabe Pharma
  • 15.18. Moderna, Inc.
  • 15.19. Novavax, Inc.
  • 15.20. Pfizer Inc.
  • 15.21. Sanofi S.A.
  • 15.22. Serum Institute of India
  • 15.23. Sinovac Biotech Ltd.
  • 15.24. Valneva SE
  • 15.25. VBI Vaccines, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIB CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIB CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIB CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEPATITIS A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA LAIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA LAIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA LAIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEASLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEASLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MEASLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RUBELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RUBELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RUBELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VARICELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VARICELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VARICELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIPID NANOPARTICLE MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRUS-LIKE PARTICLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIPHTHERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIPHTHERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIPHTHERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERTUSSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERTUSSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PERTUSSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VSV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VSV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VSV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENERAL PRACTICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENERAL PRACTICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENERAL PRACTICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SPECIALTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SPECIALTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SPECIALTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL URBAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL URBAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL URBAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LOCAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LOCAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LOCAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NATIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NATIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NATIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL IN-HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN-HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL IN-HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIRECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DIRECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIRECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CHAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CHAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL INDEPENDENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL INDEPENDENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL INDEPENDENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 301. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 322. GCC INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. GCC INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. GCC INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 325. GCC INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 326. GCC INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 327. GCC INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 328. GCC INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 329. GCC INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 330. GCC INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 331. GCC INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 332. GCC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. GCC INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 334. GCC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 335. GCC INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 336. GCC INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 337. GCC INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. GCC INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 339. GCC INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 340. GCC INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 341. GCC INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 354. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 355. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 356. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 357. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 358. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 359. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 360. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 361. EUROPEAN UNION INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 362. BRICS INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. BRICS INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. BRICS INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 365. BRICS INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 366. BRICS INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 367. BRICS INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 368. BRICS INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 369. BRICS INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 370. BRICS INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 371. BRICS INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 372. BRICS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 373. BRICS INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 374. BRICS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 375. BRICS INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 376. BRICS INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 377. BRICS INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 378. BRICS INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 379. BRICS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACI